| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.91▲ | 1.91▲ | 1.91▲ | 1.91▲ | 1.84▲ |
| MA10 | 1.91▲ | 1.91▲ | 1.91▲ | 1.90▲ | 1.77▲ |
| MA20 | 1.91▲ | 1.90▲ | 1.88▲ | 1.82▲ | 1.86▲ |
| MA50 | 1.81▲ | 1.80▲ | 1.81▲ | 1.76▲ | 2.23▼ |
| MA100 | 1.88▲ | 1.97▼ | 2.08▼ | 1.91▲ | N/A |
| MA200 | 2.53▼ | 2.30▼ | 2.28▼ | 2.16▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | 0.000▲ | 0.005▲ | 0.014▲ | 0.052▲ |
| RSI | 65.209▲ | 63.086▲ | 61.716▲ | 67.226▲ | 47.939▼ |
| STOCH | 25.261 | 41.927 | 30.649 | 53.543 | 63.699 |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -22.581▲ | -11.290▲ |
| CCI | 412.625▲ | 368.535▲ | 190.173▲ | 101.427▲ | 118.340▲ |
|
Wednesday, January 28, 2026 04:39 AM
Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ ...
|
|
Tuesday, January 27, 2026 04:47 AM
BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard ...
|
|
Friday, January 23, 2026 07:13 AM
BriaCell Therapeutics (Nasdaq: BCTX, BCTXL) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announced the closing of a public offering for gross ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 28/01/26 | 1.96 | 1.96 | 1.96 | 1.96 | 1,073 |
| 27/01/26 | 1.98 | 1.98 | 1.88 | 1.91 | 7,551 |
| 26/01/26 | 1.93 | 1.93 | 1.90 | 1.90 | 14,000 |
| 23/01/26 | 1.91 | 1.9194 | 1.90 | 1.90 | 3,849 |
| 22/01/26 | 1.93 | 1.9325 | 1.90 | 1.90 | 5,208 |
| 21/01/26 | 1.947 | 1.947 | 1.90 | 1.93 | 1,700 |
| 20/01/26 | 1.90 | 1.9756 | 1.88 | 1.88 | 32,346 |
| 16/01/26 | 1.90 | 1.98 | 1.8816 | 1.90 | 11,152 |
| 15/01/26 | 1.81 | 2.03 | 1.81 | 1.91 | 13,500 |
| 14/01/26 | 1.85 | 1.85 | 1.85 | 1.85 | 3,200 |
|
|
||||
|
|
||||
|
|